Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories, Inc. is the U.S. subsidiary of Dr. Reddy's Laboratories Limited, an Indian multinational pharmaceutical company founded in 1984 by Dr. Anji Reddy and headquartered in Hyderabad, Telangana, India. The U.S. entity is based at 107 College Road East, Princeton, New Jersey, and files corporate disclosure statements identifying Dr. Reddy's Laboratories Ltd. as its only parent. The parent is publicly listed on the Bombay and National Stock Exchanges and has NYSE-listed ADRs (ticker RDY); press and financial databases put it at roughly 27,500 employees and about US$3.7–3.8 billion in trailing-twelve-month revenue, with a market capitalization in the ~US$11 billion range.

Dr. Reddy's develops, manufactures and markets generic pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars and consumer/OTC health products. Its North American generics business is the largest single contributor (about 45% of overall sales) and covers oral solid dosage forms, injectables, complex generics such as peptides, oncology products (e.g., generic lenalidomide) and biosimilars including pegfilgrastim, bevacizumab and rituximab candidates. The company has filed hundreds of ANDAs with the FDA and operates dozens of manufacturing and R&D sites worldwide.

Patent-litigation posture: Dr. Reddy's is an operating company, not an NPE. Its tracked appearances are conventional Hatch-Waxman disputes with brand manufacturers: one as defendant and one as petitioner, both arising from the same ANDA. It is a routine two-way ANDA litigant rather than a patent assertion entity, and its cases sit in the District of Delaware, not plaintiff-friendly venues such as the Eastern District of Texas.

Notable cases: Both tracked matters concern U.S. Patent 7,326,708 ("Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor"), a Merck sitagliptin (Januvia/Janumet) patent. Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories, Inc. et al. (D. Del. 1:20-cv-00847, filed June 2020, terminated October 2021) was the infringement suit. Dr. Reddy's separately petitioned for inter partes review in Dr. Reddy's Laboratories, Inc. v. Merck Sharp & Dohme Corp. (IPR2020-01060, filed June 11, 2020), which was instituted and joined with Mylan's IPR2020-00040.